Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more.

Del Mistro A, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Girlando S, Rizzolo R, Frayle H, Trevisan M, Sani C, Burroni E, Giorgi Rossi P, Cuzick J, Ronco G; New Technologies for Cervical CancerWorking Group.

Int J Cancer. 2018 Jul 15;143(2):333-342. doi: 10.1002/ijc.31326. Epub 2018 Mar 9.

PMID:
29453769
2.

Perioperative patient outcomes in the African Surgical Outcomes Study: a 7-day prospective observational cohort study.

Biccard BM, Madiba TE, Kluyts HL, Munlemvo DM, Madzimbamuto FD, Basenero A, Gordon CS, Youssouf C, Rakotoarison SR, Gobin V, Samateh AL, Sani CM, Omigbodun AO, Amanor-Boadu SD, Tumukunde JT, Esterhuizen TM, Manach YL, Forget P, Elkhogia AM, Mehyaoui RM, Zoumeno E, Ndayisaba G, Ndasi H, Ndonga AKN, Ngumi ZWW, Patel UP, Ashebir DZ, Antwi-Kusi AAK, Mbwele B, Sama HD, Elfiky M, Fawzy MA, Pearse RM; African Surgical Outcomes Study (ASOS) investigators.

Lancet. 2018 Apr 21;391(10130):1589-1598. doi: 10.1016/S0140-6736(18)30001-1. Epub 2018 Jan 3.

PMID:
29306587
3.

Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection.

Di Paola M, Sani C, Clemente AM, Iossa A, Perissi E, Castronovo G, Tanturli M, Rivero D, Cozzolino F, Cavalieri D, Carozzi F, De Filippo C, Torcia MG.

Sci Rep. 2017 Aug 31;7(1):10200. doi: 10.1038/s41598-017-09842-6.

4.

Multimodal lung cancer screening using the ITALUNG biomarker panel and low dose computed tomography. Results of the ITALUNG biomarker study.

Carozzi FM, Bisanzi S, Carrozzi L, Falaschi F, Lopes Pegna A, Mascalchi M, Picozzi G, Peluso M, Sani C, Greco L, Ocello C, Paci E; ITALUNG Working Group.

Int J Cancer. 2017 Jul 1;141(1):94-101. doi: 10.1002/ijc.30727. Epub 2017 Apr 21.

PMID:
28387927
5.

Effectiveness of HPV vaccination in women reaching screening age in Italy.

Carozzi FM, Ocello C, Burroni E, Faust H, Zappa M, Paci E, Iossa A, Bonanni P, Confortini M, Sani C.

J Clin Virol. 2016 Nov;84:74-81. doi: 10.1016/j.jcv.2016.09.011. Epub 2016 Oct 3.

PMID:
27728850
6.

Precoagulation-assisted parenchyma-sparing laparoscopic liver surgery: rationale and surgical technique.

Francone E, Muzio E, D'Ambra L, Aschele C, Stefanini T, Sani C, Falco E, Berti S.

Surg Endosc. 2017 Mar;31(3):1354-1360. doi: 10.1007/s00464-016-5120-6. Epub 2016 Jul 21.

PMID:
27444829
7.

[HPV primary test in the cervical cancer screening: reproducibility assessment and investigation on cytological outcome of Hybrid Capture 2 borderline samples].

Burroni E, Sani C, Bisanzi S, Ocello C.

Epidemiol Prev. 2016 Mar-Apr;40(3-4):164-70. doi: 10.19191/EP16.3-4.AD03.077. Italian.

8.

HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance.

Carozzi FM, Del Mistro A, Cuschieri K, Frayle H, Sani C, Burroni E.

J Clin Virol. 2016 Mar;76 Suppl 1:S22-S28. doi: 10.1016/j.jcv.2015.10.025. Epub 2015 Nov 10. Review.

PMID:
26669512
9.

Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?

Carozzi F, Tamburrino L, Bisanzi S, Marchiani S, Paglierani M, Di Lollo S, Crocetti E, Buzzoni C, Burroni E, Greco L, Baldi E, Sani C.

J Cancer Res Clin Oncol. 2016 Jan;142(1):201-12. doi: 10.1007/s00432-015-2015-1. Epub 2015 Jul 26.

PMID:
26210155
10.

Optimal timing of valve replacement in asymptomatic severe aortic stenosis.

Bilen E, Ipek G, Ayhan H, Nacar AB, Kasapkara HA, Sani C, Basbug S, Kurt M, Bozkurt E.

J Heart Valve Dis. 2014 Sep;23(5):524-33. Review.

PMID:
25799699
11.

Human papillomavirus prevalence in paired urine and cervical samples in women invited for cervical cancer screening.

Burroni E, Bonanni P, Sani C, Lastrucci V, Carozzi F; Hpv ScreeVacc Working Group, Iossa A, Andersson KL, Brandigi L, Di Pierro C, Confortini M, Levi M, Boccalini S, Indiani L, Sala A, Tanini T, Bechini A, Azzari C.

J Med Virol. 2015 Mar;87(3):508-15. doi: 10.1002/jmv.24085. Epub 2014 Nov 21.

PMID:
25418873
12.

Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.

Gillio-Tos A, De Marco L, Carozzi FM, Del Mistro A, Girlando S, Burroni E, Frayle-Salamanca H, Giorgi Rossi P, Pierotti P, Ronco G; New Technologies for Cervical Cancer Screening Working Group.

J Clin Microbiol. 2013 Sep;51(9):2901-7. doi: 10.1128/JCM.01047-13. Epub 2013 Jun 26.

13.

Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women.

Levi M, Bonanni P, Burroni E, Bechini A, Boccalini S, Sani C, Bonaiuti R, Indiani L, Azzari C, Lippi F, Carozzi F; HPV Screevacc Working Group.

Hum Vaccin Immunother. 2013 Jul;9(7):1407-12. doi: 10.4161/hv.24337. Epub 2013 Apr 9.

PMID:
23571176
14.

Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.

Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, Girlando S, Rosso S, Naldoni C, Dalla Palma P, Zorzi M, Giorgi-Rossi P, Segnan N, Cuzick J, Ronco G; NTCC working group.

Lancet Oncol. 2013 Feb;14(2):168-76. doi: 10.1016/S1470-2045(12)70529-6. Epub 2012 Dec 21.

PMID:
23261355
15.

Codon 72 polymorphism of p53 and HPV type 16 E6 variants as risk factors for patients with squamous epithelial lesion of the uterine cervix.

Burroni E, Bisanzi S, Sani C, Puliti D, Carozzi F.

J Med Virol. 2013 Jan;85(1):83-90. doi: 10.1002/jmv.23417. Epub 2012 Nov 4.

PMID:
23124863
16.

HPV testing is an efficient management choice for women with inadequate liquid-based cytology in cervical cancer screening.

Giorgi Rossi P, Carozzi F, Collina G, Confortini M, Dalla Palma P, De Lillo M, Del Mistro A, Ghiringhello B, Gillio-Tos A, Maioli P, Pellegrini A, Schiboni ML, Segnan N, Zaffina LM, Zorzi M, Ronco G; NTCC Working Group.

Am J Clin Pathol. 2012 Jul;138(1):65-71. doi: 10.1309/AJCP6J2OEFOYTRFD.

PMID:
22706859
17.

[Human Papilloma Virus (HPV), cervical cancer incidence and screening uptake: differences among Northern, Central and Southern Italy].

Giorgi Rossi P, Chini F, Borgia P, Guasticchi G, Carozzi FM, Confortini M, Angeloni C, Buzzoni C, Buonaguro FM; Gruppo di lavoro HPV Prevalenza.

Epidemiol Prev. 2012 Mar-Apr;36(2):108-19. Review. Italian.

PMID:
22706361
18.

Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.

Carozzi FM, Burroni E, Bisanzi S, Puliti D, Confortini M, Giorgi Rossi P, Sani C, Scalisi A, Chini F.

J Clin Microbiol. 2011 Apr;49(4):1446-51. doi: 10.1128/JCM.02311-10. Epub 2011 Feb 16.

19.

The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600).

Giorgi Rossi P, Marsili LM, Camilloni L, Iossa A, Lattanzi A, Sani C, Di Pierro C, Grazzini G, Angeloni C, Capparucci P, Pellegrini A, Schiboni ML, Sperati A, Confortini M, Bellanova C, D'Addetta A, Mania E, Visioli CB, Sereno E, Carozzi F; Self-Sampling Study Working Group.

Br J Cancer. 2011 Jan 18;104(2):248-54. doi: 10.1038/sj.bjc.6606040. Epub 2010 Dec 21.

20.

Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy.

Carozzi FM, Tornesello ML, Burroni E, Loquercio G, Carillo G, Angeloni C, Scalisi A, Macis R, Chini F, Buonaguro FM, Giorgi Rossi P; HPV Prevalence Italian Working Group.

Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2389-400. doi: 10.1158/1055-9965.EPI-10-0131.

Supplemental Content

Loading ...
Support Center